Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology

Key Highlights

• Tenosynovial giant cell tumor (TGCT) are rare, locally aggressive, typically benign neoplasms of joints, bursae, and tendon sheaths. TGCT can be roughly divided into localized and diffused types. Giant cell tumor of tendon sheath is the most common form of TGCT.
• TGCT are caused by a translocation of certain parts of chromosomes 1 and 2 causing the cells to overproduce a protein called colony-stimulating factor-1 or CSF-1. there are no environmental, genetic, occupational, lifestyle, demographic or regional risk factors that have been conclusively shown to be involved with the development of these tumors.
• TGCT have a wide clinical spectrum that affect patients of all ages. The signs and symptoms of tenosynovial giant cell tumor (TGCT) can vary depending upon the exact location involved and the subtype present.
• TGCT are divided into types based on where they are and how quickly they grow. Localized giant cell tumors grow slowly. They start in smaller joints like the hand and are known as giant cell tumors of the tendon sheath (GCTTS). Diffuse giant cell tumors grow quickly and affect large joints like the knee, hip, ankle, shoulder, or elbow. These tumors are called pigmented villonodular synovitis (PVNS).
• The diagnosis of TGCT is based on a description of the symptoms and physical examinations. In addition, magnetic resonance imaging (MRI) is usually necessary in order to see the lesions and determine the best surgical intervention. Other tests that may help with the diagnosis include X-rays, synovial fluid sample from around the joints, and a biopsy of tissues from the joint.
• According to the WHO classification of TGCT, the indication is divided based on growth pattern into localized and diffused forms. There are ~90% of cases of localized TGCT, whereas ~10% of patients are from the diffused form of the disease.
• After analyzing several studies and KOL views, it was estimated that among EU4 countries and the UK, Germany accounted for the highest number of cases, followed by France, the UK, Italy, and Spain.
• The physicians compose and describe the impact of TGCT on health-related outcomes and daily living from a patient perspective. Validated questionnaires on physical function and quality of life include VAS for worst pain and stiffness in the last 24 hours.

The table given below further depicts the key segments provided in the report:

Report Summary

The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.

Tenosynovial Giant Cell Tumor Disease Understanding

Tenosynovial Giant Cell Tumor overview

Tenosynovial Giant Cell Tumor is an abnormal growth of tissue derived from the synovium that causes activation of immune cells, specifically macrophages, leading to mass formation. These tumors are often classified by their growth pattern (localized or diffused) and location (intra-or extra-articular).

TGCT have been divided macroscopically into localized or diffuse forms and appear as rubbery multinodular masses that are bounded. They have an enveloping fibrous capsule, and the transected surface of the specimen is variably colored depending on the relative proportions of fibrous tissue, hemosiderin, and pigmented foam cells. Clinical presentation of TGCT is variable, where the first sign for the patients with pathology is often a painless, slow-growing, firm, non-tender mass, which may eventually become painful and edematous as it impinges on anatomic structures. Intermittent swelling without antecedent trauma is a common symptom in the knee.

Tenosynovial Giant Cell Tumor diagnosis

The diagnosis of tenosynovial giant cell tumor is based on identifying characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests. The initial symptoms of these tumors are often vague and may go unrecognized. Consequently, there is usually a significant delay from the onset of symptoms until a diagnosis is made. Imaging techniques like X-ray and MRI are frequently used to confirm the diagnosis of TGCT, but biopsy is also used in certain cases.

The current approach to diagnosing these patients is quite similar across the 7MM, where the journey begins with a referral to an ortho-oncologist by a primary care provider upon its diagnosis. Upon diagnosis, the patients are evaluated based on their tumor-growth pattern, and assessments are done to know if they are amenable to surgery.

Recurrences of localized tenosynovial giant cell tumors are observed more commonly in the EU4 countries and the UK than in the other countries of the 7MM, like the US and Japan.

Further details related to country-based variations are provided in the report…

Tenosynovial Giant Cell Tumor Epidemiology

The Tenosynovial Giant Cell Tumor epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Tenosynovial Giant Cell Tumor, Growth Pattern-specific Incident Cases of Tenosynovial Giant Cell Tumor, Gender-specific Incident Cases of Localized Tenosynovial Giant Cell Tumor, Gender-specific Incident Cases of Diffuse Tenosynovial Giant Cell Tumor, Tumor Localization of Localized Tenosynovial Giant Cell Tumor, and Tumor Localization of Diffuse Tenosynovial Giant Cell Tumor in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2021 to 2034.

• The total number of Tenosynovial Giant Cell Tumors incident cases in the United States was around 14,500 in 2022.
• The United States contributed to the largest incident population of Tenosynovial Giant Cell Tumor, acquiring ~43% of the 7MM in 2022. Whereas EU4, the UK, and Japan accounted for around 43% and 14% of the total incident population share, respectively, in 2022.
• Among the EU4 countries, Germany accounted for the largest number of Tenosynovial Giant Cell Tumor incident cases, followed by France, whereas Spain accounted for the lowest number of incident cases in 2022.
• According to DelveInsight estimates, there were around 13,000 incident cases of localized and 1,500 incident cases of diffuse Tenosynovial Giant Cell Tumor in the United States in 2022. The incidence is projected to increase during the forecasted period.
• In EU4 and the UK, approximately 36% of the incident cases of localized Tenosynovial Giant Cell Tumors are expected to recur, whereas only 50% of the incident cases of diffuse Tenosynovial Giant Cell Tumors are expected to recur.

Tenosynovial Giant Cell Tumor (TGCT) Report Insights

• Tenosynovial Giant Cell Tumor (TGCT) Patient Population
• Type-specific and severity-specific distribution in Tenosynovial Giant Cell Tumor (TGCT)
• Country-wise Epidemiology Distribution

Tenosynovial Giant Cell Tumor (TGCT) Report Key Strengths

• Ten-year Forecast
• The 7MM Coverage
• Tenosynovial Giant Cell Tumor Epidemiology Segmentation

Tenosynovial Giant Cell Tumor (TGCT) Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Explore the key factors, trends, innovations, and developments driving the market growth, at: Tenosynovial Giant Cell Tumors (TSGCTs) Market

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Tenosynovial Giant Cell Tumor (TGCT)? What will be the growth opportunities across the 7MM with respect to the patient population of Tenosynovial Giant Cell Tumor (TGCT)?
• What is the historical and forecasted Tenosynovial Giant Cell Tumor (TGCT) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which growth pattern type is the largest contributor to the Tenosynovial Giant Cell Tumor (TGCT) patient pool?
• Which site has the most number of cases of Tenosynovial Giant Cell Tumor (TGCT) in the 7MM?

Reasons to Buy

• Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in Tenosynovial Giant Cell Tumor (TGCT) cases in varying geographies over the coming years.
• Detailed overview on growth pattern-specific, gender-specific, and tumor localization-specific cases of Tenosynovial Giant Cell Tumor (TGCT) is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.